GSK spends $1bn on rights to SiranBio’s metabolic oligonucleotide - Pharmaceutical Technology

This deal aligns with GSK's focus on addressing the complications of obesity, while restocking its pipeline amid key patent expiries. This deal strengthens GSK’s focus on addressing the complications of obesity, while restocking the company’s pipeline amid key patent expiries. GSK’s deal with SiranBio follows a growing trend of Western companies licensing assets from Chinese biotech companies. Credit: Kateryna Kon / Shutterstock.com. GSK has bought the rights to SiranBio’s metabolic oligonucleotide therapy for up to $1bn, building on the company’s efforts to indirectly break into the weight loss arena. Through this exclusive agreement, GSK will secure the global rights to…

Source: Pharmaceutical Technology